Pharmaceutical formulation for administration by inhalation comprising an androstane derivative and a beta-2-adrenoreceptor for the treatment of inflammatory and allergic conditions

Formulation pharmaceutique s'administrant par inhalation et contenant un derive d'androstane et un beta-2-adrenorecepteur pour traiter des etats inflammatoires et allergiques

Abstract

According to one aspect of the invention, there is provided a pharmaceutical formulation for administration by inhalation comprising a compound of formula (I), or a solvate thereof, together with a long-acting β2-adrenoreceptor agonist which formulation has a therapeutically useful effect in the treatment of inflammatory disorders of the respiratory tract over a period of 24 hours or more.
Un aspect de l'invention concerne une formulation pharmaceutique s'administrant par inhalation et contenant un composé représenté par la formule (I) ou un de ses solvates, avec un agoniste du β2-adrénorécepteur à action prolongée, cette formulation exerçant un effet utile sur le plan thérapeutique pour traiter des troubles inflammatoires des voies respiratoires pendant une période égale ou supérieure à 24 heures.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (8)

    Publication numberPublication dateAssigneeTitle
    EP-0416951-A1March 13, 1991Glaxo Group LimitedMédicaments comprenant salmeterol et fluticason
    GB-2140800-ADecember 05, 1984Glaxo Group LtdPhenethanolamine derivatives
    US-2002173496-A1November 21, 2002Keith BiggadikeFormulation containing novel anti-inflammatory androstane derivative
    US-2002177581-A1November 28, 2002Keith BiggadikeNovel anti-inflammatory androstane derivative
    WO-02066422-A1August 29, 2002Glaxo Group LimitedPhenethanolamine derivatives for treatment of respiratory diseases
    WO-02070490-A1September 12, 2002Glaxo Group LimitedAgonistes de beta-adrenocepteurs
    WO-0212265-A1February 14, 2002Glaxo Group Limited6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT
    WO-0212266-A1February 14, 2002Glaxo Group LimitedDerives de 17-beta-carbothioate-17-alpha-arylcarbonyloxyloxy androstane utilises comme anti-inflammatoires

NO-Patent Citations (2)

    Title
    MOLEN VAN DER T ET AL: "EFFECTS OF THE LONG ACTING BETA AGONIST FORMOTEROL ON ASTHMA CONTROL IN ASTHMATIC PATIENTS USING INHALED CORTICOSTEROIDS", THORAX, LONDON, GB, vol. 52, no. 6, 1997, pages 535 - 539, XP000992767
    NAEDELE-RISHA R ET AL: "Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long-acting beta-agonists with inhaled corticosteroids.", THE JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION. UNITED STATES SEP 2001, vol. 101, no. 9, September 2001 (2001-09-01), pages 526 - 533, XP009009641, ISSN: 0098-6151

Cited By (5)

    Publication numberPublication dateAssigneeTitle
    US-8933060-B2January 13, 2015Cipla LimitedCombination of azelastine and ciclesonide for nasal administration
    US-8937057-B2January 20, 2015Cipla LimitedCombination of azelastine and mometasone for nasal administration
    US-8969547-B2March 03, 2015Zhejiang Tiantai Aurisco Pharmaceuticals Co. Ltd., Shanghai Aurisco Industry Co., Ltd.Method for preparing fluticasone furoate
    US-9259428-B2February 16, 2016Cipla LimitedCombination of azelastine and fluticasone for nasal administration
    WO-2012079275-A1June 21, 2012浙江省天台县奥锐特药业有限公司, 上海奥锐特实业有限公司Procédé de synthèse de furaote de fluticasone